Efficacy And Safety Of Continuous Erythropoietin Receptor Activator In Renal Anemia:A Meta-analysis

Background and Aim:Anemia is a common complication of patients with chronic kidney disease and an independent risk factor that increases their cardiovascular risk and death risk.For patients with chronic kidney disease anemia,erythropoietin is the first choice.Compared with traditional erythropoietin,continuous erythropoietin receptor activator(CERA)has the characteristics of prolonging the administration time and maintaining hemoglobin stability.However,the long-term efficacy and safety of CERA in the treatment of renal anemia are still unclear.Therefore,this article intends to search the literature on the efficacy and safety of CERA in the treatment of renal anemia for meta-analysis.Method:Use the Cochrane systematic review method to search Medline,Pub Med,Embase,The Cochrane Library,CNKI,Wanfang Database,and China Biomedical Database.The search scope is from the establishment of the database to December2020 and collect persistent erythropoietin receptors.Relevant literature on the treatment of renal anemia with activators.Use Review Manager for data analysis.For statistical data results,Begg’s test is used for publication bias analysis,and metanif command is used for sensitivity analysis.Result:In the end we included 15 studies,including 6736 patients(including 3,600 in the CERA group and 3,136 in the control group).In terms of efficacy,the results of Meta analysis showed that for patients with renal anemia,the hemoglobin compliance rate,hemoglobin change from baseline,and hemoglobin level at the end of treatment were similar in the CERA group compared with the control group,and the difference was not statistically significant.In terms of safety,the results of the Meta analysis showed that for patients with renal anemia,the CERA group compared with the control group had similar all-cause mortality,cardiovascular mortality,hypertension,major adverse cardiovascular events,and cancer risk.The difference was not statistically significant.Conclusion:Compared with other ESAs,CERA can maintain hemoglobin stability in patients with CKD anemia,and its efficacy and safety are comparable to other ESAs.